Welcome to our dedicated page for Lemaitre Vasculr news (Ticker: LMAT), a resource for investors and traders seeking the latest updates and insights on Lemaitre Vasculr stock.
LeMaitre Vascular, Inc. provides devices, implants, and services for the treatment of peripheral vascular disease. The company develops, manufactures, and markets disposable and implantable vascular devices for vascular surgeons, with products used in arteries and veins.
Recurring LMAT news includes quarterly financial results, guidance, dividend declarations, and management presentations at healthcare investor conferences. Company updates also discuss product categories such as Artegraft, grafts, valvulotomes, and carotid shunts, along with sales activity across the Americas, EMEA, and Asia Pacific.
LeMaitre Vascular, Inc. (Nasdaq: LMAT) will release its Q1 2021 financial results on April 29, 2021, after market close. A conference call is scheduled for 5:00 PM EDT on the same day to discuss the financial results, business highlights, and outlook. Interested parties can access the call via phone or a live webcast. LeMaitre is known for its vascular devices, addressing the needs of vascular surgeons and catering to a global patient base affected by peripheral vascular disease.
LeMaitre Vascular announced that CFO JJ Pellegrino will present at the 20th Annual Needham Virtual Healthcare Conference on April 12, 2021, at 9:30 AM EDT. The company specializes in devices and services for treating peripheral vascular disease, which affects over 200 million people globally. LeMaitre develops and markets both disposable and implantable vascular devices tailored for vascular surgeons. For further information, visit www.lemaitre.com.
LeMaitre (Nasdaq: LMAT) reported strong Q4 2020 results, with sales of $37.5 million, a 24% increase year-over-year. Operating income surged 94% to $9.5 million, resulting in a net income of $7.0 million and earnings of $0.34 per diluted share. Debt was reduced by $21.5 million, improving the balance sheet. Despite gross margin slightly declining to 65%, the company achieved record sales driven by acquisitions and strong performance in the Americas. For Q1 2021, LeMaitre projects sales between $33.8 and $36.8 million, with an expected earnings per share of $0.24 to $0.31.
LeMaitre Vascular (Nasdaq:LMAT) is set to participate in four key investor conferences in February and March 2021. David Roberts, President, will present at:
- SVB Leerink's Global Healthcare Conference on February 26, 2021, at 8:40 AM EST
- Barclays Global Healthcare Conference on March 9, 2021, at 1:50 PM EST
- 33rd Annual Roth Conference on March 15, 2021, on demand
- Oppenheimer's Healthcare Conference on March 16, 2021, at 3:10 PM EDT
LeMaitre Vascular specializes in devices and services for peripheral vascular disease, helping over 200 million people globally.
LeMaitre Vascular, Inc. (Nasdaq:LMAT) will release its fourth quarter 2020 financial results on February 25, 2021, post-market. A conference call is scheduled for the same day at 5:00 PM ET to discuss results and company outlook. Investors can dial in or access the call via a webcast at www.lemaitre.com/investor. LeMaitre is known for its devices addressing peripheral vascular disease, a condition impacting over 200 million individuals globally, and offers a diversified product portfolio for vascular surgeons.
LeMaitre Vascular (Nasdaq:LMAT) announced its participation in two upcoming investor conferences in January 2021. CFO JJ Pellegrino will present at the 23rd Annual Needham Virtual Growth Conference on January 11, 2021, at 11:30 AM ET, and at the Sidoti Winter 2021 Investor Conference on January 14, 2021, at 10:45 AM ET. The company, which specializes in devices for treating peripheral vascular disease, aims to inform and engage investors about its market position and growth strategies.
LeMaitre Vascular announced that President David Roberts will present at the Jefferies Virtual London Healthcare Conference on November 18, 2020, at 12:25 PM ET. The company specializes in devices and services for treating peripheral vascular disease, which impacts over 200 million people globally. LeMaitre develops both disposable and implantable vascular devices, focusing on the needs of vascular surgeons.
LeMaitre Vascular (Nasdaq:LMAT) announced its participation in two investor conferences this November. David Roberts, President, will present at the Stifel Virtual Healthcare Conference on November 16, 2020, at 8:00 AM ET. Meanwhile, JJ Pellegrino, Chief Financial Officer, is set to speak at the Canaccord Genuity 2020 Medical Technologies & Diagnostics Forum on November 19, 2020, at 9:30 AM ET. LeMaitre Vascular specializes in devices for treating peripheral vascular disease, serving over 200 million people globally.
LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced its Q3 2020 results with sales reaching $36.4 million, reflecting a 25% increase. Operating income surged 70% to $10.0 million, with a net income of $7.5 million, a 45% rise. The company declared a quarterly dividend of $0.095/share. Growth was driven by acquisitions and recovery in elective surgeries. However, gross margin fell to 62.3% from 69.3% a year prior. Guidance for Q4 anticipates sales between $34.0 million and $38.0 million.
LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced it will release its third quarter 2020 financial results on October 29, 2020, after market close. A conference call is scheduled for 5:00 PM EDT that day to discuss the financial results and the company's outlook. Interested parties can join the call at 844-239-5284 or access the live webcast through their investor relations website.
LeMaitre Vascular specializes in devices for the treatment of peripheral vascular disease, a condition impacting over 200 million people globally.